Castleark Management LLC boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,630 shares of the company’s stock after buying an additional 2,370 shares during the period. Castleark Management LLC owned approximately 0.11% of Krystal Biotech worth $8,171,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. OMERS ADMINISTRATION Corp acquired a new stake in Krystal Biotech during the 1st quarter worth about $1,059,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Krystal Biotech during the 1st quarter valued at about $1,205,000. Renaissance Technologies LLC boosted its position in shares of Krystal Biotech by 190.9% during the 1st quarter. Renaissance Technologies LLC now owns 9,600 shares of the company’s stock valued at $2,480,000 after purchasing an additional 6,300 shares in the last quarter. Atika Capital Management LLC bought a new stake in shares of Krystal Biotech during the 1st quarter valued at about $2,745,000. Finally, Sei Investments Co. grew its stake in Krystal Biotech by 44.1% during the first quarter. Sei Investments Co. now owns 46,570 shares of the company’s stock worth $12,030,000 after purchasing an additional 14,260 shares during the period. Institutional investors own 86.29% of the company’s stock.
Insider Transactions at Krystal Biotech
In related news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 over the last quarter. Corporate insiders own 13.10% of the company’s stock.
Krystal Biotech Price Performance
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, analysts expect that Krystal Biotech, Inc. will post 7.31 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have weighed in on KRYS. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $360.67.
Check Out Our Latest Analysis on KRYS
Krystal Biotech Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
